Daclatasvir Archives

21 July 2017

ITPC MENA IN THE REGIONAL CONSULTATION ON ACCELERATING ACCESS TO THE CONTIUUM OF HIV …

Advocacy, AIDS, ARV, Daclatasvir, Dolutegravir, Guidelines, HIV, Middle East, Morocco, North Africa 81 Views

Beirut, Lebanon, 12–14 July 2017 By the end of 2015, the estimated number of people living with HIV in the Region had reached 330 000. With a continuously growing epidemic coupled with low coverage

20 July 2017

New WHO Guidance Report- Treatment Failure and Drug Resistance

Advocacy, AIDS, ARV, Daclatasvir, Dolutegravir, Guidelines, HIV, Pathology, The Global Fund 81 Views

WHO urges action against HIV drug resistance threat 20 JULY 2017 | GENEVA – WHO alerts countries to the increasing trend of resistance to HIV drugs detailed in a report based on national surveys conducted

23 January 2017

Amendment of the TRIPS Agreement

Advocacy, ARV, Daclatasvir, Dolutegravir, HCV, Health Financing, Hepatitis, HIV, Intellectual Proprety, Pathology, Sofosbuvir, TB 83 Views

WTO members on 6 December 2005 approved changes to the WTO’s intellectual property (TRIPS) agreement in order to make permanent a decision on patents and public health originally adopted in 2003. This was formally

26 June 2015

Launch of Moroccan Generic Sofosbuvir: A Victory for the Wide-spread Use HCV Treatmen…

ARV, Daclatasvir, HCV, Hepatitis, Intellectual Proprety, Morocco, North Africa, Sofosbuvir 112 Views

According to the Ministry of Health, 625,000 people are infected by HCV, 1.6% of the general population of Morocco. Of those infected, 267,000 people have active chronic infection requiring treatment. Until recently, the management

20 May 2015

Treatment Advocates Denounce Gilead’s Embargo against Thousands of Tunisians Sufferin…

Advocacy, ARV, Daclatasvir, HCV, Health Financing, Hepatitis, Intellectual Proprety, News, North Africa, Sofosbuvir 79 Views

The Tunisian Association of Fight against STDs and AIDS (ATL Tunis) and the International Treatment Preparedness Coalition in MENA Region (ITPC-MENA) denounce the refusal of Gilead Sciences to make their drug against the Hepatitis

10 July 2014

The first Middle East and North Africa Community Advisory Board (MENA-CAB)

Advocacy, AIDS, Algeria, ARV, Daclatasvir, Dolutegravir, Guidelines, HIV, Intellectual Proprety, Libya, Middle East, Morocco, North Africa, REGION, Tunisia 84 Views

Casablanca, Morocco, 28 June-01 July 2014 Despite the fact that HIV prevalence in the countries of the Middle East and North Africa is believed to be low at least among the General Population, the